Trinity Biotech PLC
NASDAQ:TRIB
Intrinsic Value
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. [ Read More ]
The intrinsic value of one TRIB stock under the Base Case scenario is 4.34 USD. Compared to the current market price of 2.04 USD, Trinity Biotech PLC is Undervalued by 53%.
Valuation Backtest
Trinity Biotech PLC
Run backtest to discover the historical profit from buying and selling TRIB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Trinity Biotech PLC's business.
What risks and challenges
does Trinity Biotech PLC face in the near future?
Summarize the latest earnings report
of Trinity Biotech PLC.
Provide P/E
for Trinity Biotech PLC and its competitors.
Balance Sheet Decomposition
Trinity Biotech PLC
Current Assets | 43.8m |
Cash & Short-Term Investments | 6.3m |
Receivables | 16.7m |
Other Current Assets | 20.9m |
Non-Current Assets | 19.8m |
PP&E | 1.8m |
Intangibles | 16.2m |
Other Non-Current Assets | 1.8m |
Current Liabilities | 12.7m |
Accounts Payable | 10.6m |
Other Current Liabilities | 2.1m |
Non-Current Liabilities | 68.3m |
Long-Term Debt | 65.2m |
Other Non-Current Liabilities | 3.1m |
Earnings Waterfall
Trinity Biotech PLC
Revenue
|
61.4m
USD
|
Cost of Revenue
|
-40.3m
USD
|
Gross Profit
|
21.1m
USD
|
Operating Expenses
|
-38.4m
USD
|
Operating Income
|
-17.2m
USD
|
Other Expenses
|
-11.4m
USD
|
Net Income
|
-28.6m
USD
|
Free Cash Flow Analysis
Trinity Biotech PLC
What is Free Cash Flow?
TRIB Profitability Score
Profitability Due Diligence
Trinity Biotech PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Trinity Biotech PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
TRIB Solvency Score
Solvency Due Diligence
Trinity Biotech PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Trinity Biotech PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TRIB Price Targets Summary
Trinity Biotech PLC
According to Wall Street analysts, the average 1-year price target for TRIB is 3 USD .
Shareholder Return
TRIB Price
Trinity Biotech PLC
Average Annual Return | 22.12% |
Standard Deviation of Annual Returns | 144.46% |
Max Drawdown | -94% |
Market Capitalization | 77.9m USD |
Shares Outstanding | 38 207 600 |
Percentage of Shares Shorted | 1.8% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.
Contact
IPO
Employees
Officers
The intrinsic value of one TRIB stock under the Base Case scenario is 4.34 USD.
Compared to the current market price of 2.04 USD, Trinity Biotech PLC is Undervalued by 53%.